In a trial exploring futibatinib in previously treated cholangiocarcinoma patients with FGFR alterations, 20/28 patients carrying FGFR2 fusions experienced tumor shrinkage and 7/28 confirmed PR. Here, FGFR2 is linked to cholangiocarcinoma.